Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

BCL-2 inhibitor TQB3909 combined with JAK inhibitors in patients with intermediate- or high-risk myelofibrosis: A two-cohort, open-label, Phase ib/II, multicenter study

View Full Paper
Ask AI
Bookmark
Share

Authors

JHJian Huang

Discussion

Loading...

Member takes

Overview

Open-label trial shows TQB3909 with JAK inhibitors improves hemoglobin and reduces spleen size in myelofibrosis patients, suggesting enhanced therapy options.

Key Points

  • Significant spleen size reduction observed in myelofibrosis patients indicates enhanced treatment efficacy.
  • In this cohort, 81.8% showed spleen size reduction, with half achieving over 20% decrease during the study.
  • Observational trial assessed the combination of BCL-2 inhibitor TQB3909 and JAK inhibitors on clinical outcomes.
  • TQB3909 combined with JAK inhibitors highlights potential for improved hemoglobin levels and manageable toxicities.

Cite This Study

Jian Huang (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7c0https://doi.org/10.1182/blood-2025-2034
View Full Paper
Ask AI
Bookmark
Share